Source: LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PharmAla Biotech will be the exclusive supplier of GMP LaNeo MDMA and Engineering MDMA to InterVivo Solutions and its client companies
  • With Transpharmation, they form the largest boutique neuroscience-specialized in vivo CRO
  • Through the agreement, PharmAla will give its GMP, clinical-grade LaNeo MDMA to InterVivo and its client companies
  • This all allows for simple access to MDMA for research purposes for all InterVivo’s clients at a reduced price
  • PharmAla Biotech Holdings is sitting at C$0.04 at close as of August 4

PharmAla Biotech (MDMA) will be the exclusive supplier of GMP LaNeo MDMA and Engineering MDMA to InterVivo Solutions and its client companies and affiliates.

InterVivo Solutions is a well-established preclinical contract research organization (CRO) with expertise in neuropsychiatric and neurological diseases.

Together with Transpharmation, they form the largest boutique neuroscience-specialized in vivo CRO.

“Our hope is this will streamline and further propel our client’s research efforts to uncover and optimize the key properties of psychedelics and entactogenic medicines,” said Sal Lemus, Director of Sales and Marketing at InterVivo Solutions.

Through this agreement, PharmAla will provide its GMP, clinical-grade LaNeo™ MDMA to InterVivo and its client companies, as well as engineering MDMA for animal research.

The agreement allows for simple access to MDMA for research purposes for all InterVivo’s clients at reduced prices and guarantees access to MDMA that can be taken from preclinical to human clinical research.

“As a current client of InterVivo, we have seen the excellence of their work first-hand. We’ve been impressed with both their scientific rigour and the speed with which they have developed data sets to support our novel IP,” said Nick Kadysh, PharmAla’s CEO.

“I’m thrilled that we have been named the exclusive supplier of MDMA for both InterVivo and their research clients […].”

PharmAla Biotech Holdings is a biotechnology company focused on researching, developing, and manufacturing MDXX class molecules, including MDMA.

PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials and to develop novel drugs in the same class.

PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.

The company has worked to build what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API) and drug product formulation.

InterVivo Solutions (IVS) is a preclinical in vivo CRO providing research services using translational animal models for efficacy, pharmacokinetics, safety and toxicology, including bioanalytical and imaging support.

PharmAla Biotech Holdings is sitting at C$0.04 at close as of August 4.


More From The Market Herald
Medicenna - President and CEO, Fahar Merchant.

" Medicenna (TSX:MDNA) closes US$20 million public offering

Medicenna Therapeutics Corp. (MDNA) has closed its

" Titan Medical (TSX:TMD) reports Q2 2022 financial results

Titan Medical (TMD) released financial results for the three and six months ended June 30, 2022.

" Aleafia Health (TSX:AH) earns record quarter-over-quarter revenue in Q1 2023

Aleafia Health (AH) reported its financial results for the three months ended June 30, 2022.

" UniDoc (CSE:UDOC) signs agreement to provide telehealth services in Kenya

UniDoc Health (UDOC) has signed a master equipment deployment and services agreement with Claron Health to provide telehealth services in Kenya.